Department of Internal Medicine, Mayo Clinic, Rochester,Minnesota.
Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester,Minnesota.
Infect Control Hosp Epidemiol. 2019 Jun;40(6):632-638. doi: 10.1017/ice.2019.94. Epub 2019 Apr 30.
Central-line-associated bloodstream infections (CLABSIs) are a known complication of central venous access. Pulmonary artery catheters (PAC) are frequently used in pre-heart-transplant patients, but the rate of CLABSI in this population is unknown. We sought to estimate the rate of CLABSI and identify factors associated with development of infection in patients actively listed for heart transplantation with a PAC.
Retrospective cohort study.
This study was conducted in 3 intensive care units at an academic tertiary-care center in Minnesota.
61 pre-heart-transplant patients in an intensive care unit with a PAC in place from January 2013 to December 2016, totaling 219 PACs.
At-risk patients, pertinent risk factors, and demographic data were obtained using Mayo Clinic's Unified Data Platform. CLABSIs were identified through internal infection prevention and control data. Characteristics of PAC use and infection rate were collected and analyzed using Kaplan-Meier estimates and time-dependent Cox models.
Among pre-heart-transplant patients with a PAC, there were 14 CLABSIs, for an infection rate of 5.46 of 1,000 PAC days (95% confidence interval [CI], 2.98-9.15). The most common causative organism was coagulase-negative Staphylococcus (79%). In unadjusted analyses, CLABSI was associated with shorter time to transplant (hazard ratio [HR], 2.49; P = .027), but not mortality (HR, 1.79; P = .355).
The rate of CLABSI with PAC is high. Prolonged PAC use in the pre-heart-transplant population should be revisited.
中心静脉导管相关性血流感染(CLABSI)是中心静脉置管的已知并发症。肺动脉导管(PAC)常用于心脏移植前的患者,但该人群中 CLABSI 的发生率尚不清楚。我们旨在评估有 PAC 的心脏移植候选患者中 CLABSI 的发生率,并确定与感染发生相关的因素。
回顾性队列研究。
这项研究在明尼苏达州一家学术性三级保健中心的 3 个重症监护病房进行。
2013 年 1 月至 2016 年 12 月期间,重症监护病房中有 61 例心脏移植前患者,共放置了 219 根 PAC,这些患者都存在感染风险。
使用梅奥诊所的统一数据平台获取高危患者、相关危险因素和人口统计学数据。通过内部感染预防和控制数据确定 CLABSI。使用 Kaplan-Meier 估计和时间依赖性 Cox 模型收集和分析 PAC 使用和感染率的特征。
在有 PAC 的心脏移植前患者中,有 14 例 CLABSI,感染率为每 1000 个 PAC 天 5.46 例(95%置信区间[CI],2.98-9.15)。最常见的病原体是凝固酶阴性葡萄球菌(79%)。在未调整的分析中,CLABSI 与移植前时间较短相关(风险比[HR],2.49;P =.027),但与死亡率无关(HR,1.79;P =.355)。
PAC 相关 CLABSI 的发生率较高。应重新审视心脏移植前人群中 PAC 的长期使用。